Stephanie Romero
Family · Gulfport, MSNPI 1710976162
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,000 of the $28,282 with a category attached, or 77.8%. Fresenius USA Marketing, Inc. accounts for 90.2% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $16,432 and has fallen 98.4% since, to $264 in 2025. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $193.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$26K
- Bayer$352
- Vifor Pharma, Inc.$342
- AstraZeneca$296
- Revance Therapeutics, Inc.$167
- Nxstage Medical, Inc.$166
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$22,00078%
- Travel & lodging$2,4919%
- Food & beverage$3,69213%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 34 | $25,515 |
| Bayer | 16 | $352 |
| Vifor Pharma, Inc. | 14 | $342 |
| AstraZeneca | 6 | $296 |
| Revance Therapeutics, Inc. | 3 | $167 |
| Nxstage Medical, Inc. | 2 | $166 |
| GSK | 7 | $159 |
| Amgen(2 entities) | 8 | $151 |
| Akebia Therapeutics Inc | 9 | $143 |
| OPKO Pharmaceuticals, LLC | 9 | $136 |
| AbbVie | 2 | $131 |
| Calliditas Therapeutics US Inc. | 5 | $121 |
| Mallinckrodt Hospital Products Inc. | 6 | $100 |
| Neurelis, Inc. | 1 | $91 |
| Daiichi Sankyo Inc. | 5 | $88 |
| Lilly USA, LLC | 5 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Johnson & Johnson | 2 | $36 |
| Aurinia Pharma U.S., Inc. | 2 | $29 |
| Novo Nordisk | 1 | $18 |
| Cormedix Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Medtronic | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $14 |
| Renalytix AI, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,282 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 82 | $187,055 |
| AuryxiaFerric Citrate | 22 | $39,821 |
| OzempicSemaglutide | 30 | $31,548 |
| Sevelamer Carbonate | 128 | $19,445 |
| MounjaroTirzepatide | 16 | $16,078 |
| EliquisApixaban | 12 | $11,415 |
| Calcium Acetate | 46 | $6,649 |
| Clonidine | 13 | $1,071 |
| Midodrine Hcl | 16 | $834 |
| Nifedipine ErNifedipine | 30 | $756 |
| Ropinirole Hcl | 17 | $712 |
| Metoprolol Succinate | 32 | $603 |
| Gabapentin | 62 | $591 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 20 | $576 |
| Hydralazine Hcl | 38 | $521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $25,515 | $187,05582 claims |
| Akebia Therapeutics IncAuryxia | $143 | $39,82122 claims |
| Novo NordiskOzempic | $18 | $31,54830 claims |
| Lilly USA, LLCMounjaro | $83 | $16,07816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Gulfport
- Ashley HouseGulfport$14K
- Chaeleena LaddGulfport$14K
- Justine HuntGulfport$12K
- Laura StevensGulfport$11K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.